Abstract:Objective To investigate the prevalence and clinical significance of different subtypes (IgG,IgM and IgA) of anticardiolipin antibodies (aCL) and anti-β2-glycoprotein Ⅰ antibodies (aβ 2GP1),as well as lupus anticoagulant (LA) in systemic lupus erythematosus (SLE).Methods IgG/IgM/IgA,IgG,IgM,IgA aCL and anti-β2GP1 were tested by enzyme-linked immunosorbent assay (ELISA) in 100 patients with SLE (42 patients were diagnosed as secondary antiphospholipid syndrome),44 healthy controls and 32 patients with other connective tissue diseases excluding SLE and antiphospholipid syndrome (APS).Meanwhile,LA was tested by modified Dilute Russell's viper venom time (dRVVT).The correlation between antiphospholipid antibodies and clinical manifestation was analyzed by Spearman correlation analysis.The postiverate of antiphospholipid antibodies in SLE patients,health controls and patients with other connective tissue diseases were compared by chi square test.The concentrations of antiphospholipid antibodies in different groups were compared using independent sample Kruskal Wallis test.The diagnostic efficacy of antiphospholipid antibodies in SLE patients was analyzed by crosstable using clinical diagnosis of APS as gold standard.P ＜ 0.05 was considered statistically significant.Results The prevalence of IgG aCL (x2 =15.031,P ＜ 0.001),IgA/G/M (x2 =11.678,P =0.003) and IgA (x2 =6.17,P =0.036) antiβ2GP1 were significantly higher in patients with SLE than in the other two groups.IgA/G/M (r =0.207,P=0.039),IgG (r=0.230,P=0.021) and IgA (r=0.217,P=0.030) aCL,IgA/G/M (r=0.218,P=0.029) and IgA (r =0.255,P =0.01) anti-β2GP1,as well as LA (r =0.233,P =0.02) were associated with thrombotic events.IgA/G/M anti-β2GP1 (r =0.22,P =0.029) and LA (r =0.254,P =0.011) were associated with pathological pregnancy.23.1％ (6/26) aCL positive SLE patients were IgM and/or IgA aCL positive.53.6％ (15/28) anti-β2GP1 positive SLE patients were IgM and/or IgA antiβ2GP1 positive.In SLE patients,the specificity and sensitivity of IgA/G/M aCL for APS were 98.3％ and 26.2％,respectively.The specificity and sensitivity of IgA/G/M anti-β2GP1 were 84.5％ and 40.5％,respectively.The specificity of at least two isotypes positive for APS (both aCL and anti-β2GP1 were 98.3％),was higher than IgG aCL (94.8％) or anti-β2GP1 (93.1％).The sensitivity of at least one isotype of aCL (47.6％) or anti-β2GP1 (42.9％) positive for APS were higher than IgG aCL (40.5％)and anti-β2GP1 (21.4％).Conclusions IgG and IgM aCL together would be better than IgA/G/M aCL for APS screening.IgA/G/M anti-β2GP1 would be better for APS screen due to higher sensitivity and strong association with thromboembolic events and pathologic pregnance.IgA aCL or anti-β2GP1 was associated with thromboembolic events.IgA aCL or anti-β2GP1 would be useful for APS diagnosis in IgG and IgM aCL or anti-β2GPl negative patients.

Thrombin generation assay and lupus anticoagulant synergically distinguish populations of patients with antiphospholipid antibodies

Thrombin Generation Assay in Antiphospholipid Antibodies Positive Subjects as a Personalized Thrombotic Risk Assessment: State of the Art and Perspectives

Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity?

Prevalence, persistence and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus

Antibody Profiles Comprising Anti Phosphatidylserine/prothrombin Differently Affect Thrombin Generation and Protein C Resistance in Antiphospholipid Antibody Carriers

Tetra Positive Thrombotic Antiphospholipid Syndrome: Major Contribution of Anti‐phosphatidyl‐serine/prothrombin Antibodies to Lupus Anticoagulant Activity

The lupus anticoagulant titer is associated with elevated antiphosphatidylserine/prothrombin immunoglobulin‐M isotype antibody levels

Clinical Significance of Different Antiphospholipid Antibody Isotypes in Systemic Lupus Erythematosus

Thrombosis in Antiphospholipid Syndrome: Current Perspectives and Challenges in Laboratory Testing for Antiphospholipid Antibodies

The estimated prevalence of antiphospholipid antibodies and criteria-antiphospholipid syndrome in subjects with renal thrombotic microangiopathy

Laboratory Profile of Lupus Anticoagulant Positive Cases and its Association with Clinical Presentation- Experience from a Tertiary Care Centre in Southern India

Antiphospholipid antibody testing

[Antiphospholipid antibodies: clinical significance and biological diagnosis]

Deciphering the clinical significance of longitudinal antiphospholipid antibody titers

Taipan snake venom time has high sensitivity for lupus anticoagulants in non‐anticoagulated, triple positive antiphospholipid syndrome patients

Clinical Performance of Antibodies to Prothrombin and Thrombin in Chinese Patients with Antiphospholipid Syndrome: Potential Interest in Discriminating Patients with Thrombotic Events and Non-Thrombotic Events

Non-criteria Antiphospholipid Antibodies in Antiphospholipid Syndrome: Diagnostic Value Added

Clinical significance and prevalence of some coagulation-related factors' antibodies in patients with antiphospholipid syndrome or systemic lupus erythematosus with thrombosis

Insight into the Hypercoagulable State of High‐risk Thrombotic APS Patients: Contribution of Aβ2gpi and Aps/pt Antibodies

Prevalence of Aphosphatidylserine/prothrombin Antibodies and Association with Antiphospholipid Antibody Profiles in Patients with Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis.

Anti-phosphatidylserine/prothrombin complex antibodies (aps/pt) increase the risk for thrombosisbased on lupus anticoagulantpositivity